Gilberto Lopes - Concepedia

Author

Gilberto Lopes

Also Known As

G Lopes, G de Lima Lopes, G. D. Lopes, G. De Lima Lopes, G. Lopes, G. de L. Lopes, G. de Lima Lopes, Gilberto DE LIMA LOPES Jr, Gilberto De Lima Lopes, Gilberto De Lima Lopes Jr.

469

Publications

12.5K

Citations

H-Index

Concepts

All Affiliations

University of Miami Sylvester Comprehensive Cancer Center Johns Hopkins University University of Washington Dana-Farber Cancer Institute

About

Gilberto Lopes is an author at University of Miami specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	37	3.9K
2	Public Health	10	10	2.4K
3	Health Sciences	3	3	390
4	Nursing	1	1	11
5	African American Studies	1	1	23

Gilberto Lopes

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, The Lancet EpidemiologyCancer EpidemiologyMedicineGlobal HealthEpidemiology Of Cancer	2020	1.8K
Planning cancer control in Latin America and the Caribbean Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević, The Lancet Oncology Preventive MedicineMedicineGlobal HealthEpidemiology Of CancerCancer Prevention	2013	496
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, The Lancet Oncology	2021	428
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study Vivek Subbiah, Mimi I. Hu, Lori J. Wirth, The Lancet Diabetes & Endocrinology MedicineThyroid DiseasePathologyCancer TreatmentThyroid Hormone	2021	330
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study Gilberto de Castro, Iveta Kudaba, Yi‐Long Wu, Journal of Clinical Oncology	2022	281
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 Michael A. Thompson, Jeffrey P. Henderson, Pankil Shah, JAMA Oncology	2021	184
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study Donna R. Rivera, Solange Peters, Orestis A. Panagiotou, Cancer Discovery	2020	138
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With<i>EGFR</i>-Mutated Advanced Non–Small Cell Lung Cancer Pedro Nazareth Aguiar, Benjamin Haaland, Wungki Park, JAMA Oncology	2018	119
A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer Peter J. Hosein, Gilberto Lopes, Vitor H. Pastorini, American Journal of Clinical Oncology	2012	99

Page 1